Vipin Garg, Altimmune CEO

Al­tim­mune says ‘dou­ble G’ drug has even bet­ter lean mass preser­va­tion da­ta in obe­si­ty tri­al up­date

OR­LAN­DO – Al­tim­mune is back with a full Phase 2 analy­sis of its “dou­ble G” drug pemvidu­tide, with the com­pa­ny tout­ing it is much bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.